title: Preconditioning the hyperlipidemic myocardium: fact or fantasy?
abstract: Ischemic heart disease is a leading cause of death worldwide. Myocardial ischemia results in reduced coronary flow, followed by diminished oxygen and nutrient supply to the heart. Reperfusion to an ischemic myocardium often augments the ischemic damage, known as ischemia-reperfusion (I/R) injury. Number of studies demonstrated that the hyperlipidemic myocardium is rather sensitive and more vulnerable to I/R-induced myocardial injury. Repeated brief ischemia and reperfusion cycles, termed as ischemic preconditioning, given before a sustained ischemia is known to reduce myocardial damage occur as a result of I/R. A plethora of evidence supports the fact that preconditioning is one of the promising interventional strategies having an ability to limit I/R-induced myocardial injury. Despite this fact, the preconditioning-mediated cardioprotection is blunted in chronic hyperlipidemic condition. This suggests that preconditioning is moderately a 'healthy heart protective phenomenon'. The mechanisms by which chronic hyperlipidemia abrogates cardioprotective effects of preconditioning are uncertain and are not completely understood. The impaired opening of mitochondrial-K(ATP) channels, eNOS uncoupling and excessive generation of superoxides in the hyperlipidemic myocardium could play a role in attenuating preconditioning-mediated myocardial protection against I/R injury. Moreover, hyperlipidemia-induced loss of cardioprotective effect of preconditioning is associated with redistribution of both sarcolemmal and mitochondrial Connexin 43. We addressed, in this review, the potential mechanisms involved in hyperlipidemia-induced impairment of myocardial preconditioning. Additionally, novel pharmacologic interventions to attenuate hyperlipidemia-associated exaggerated I/R-induced myocardial injury have been discussed.
authors.affiliation: Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences (RITS), Sirsa, India. pbala2006@gmail.com
authors.forename: Pitchai
authors.initials: P
authors.lastname: Balakumar
authors.forename: Lalita
authors.initials: L
authors.lastname: Babbar
mesh_terms: D000818:Animals; D018031:Connexin 43 / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000473:pathology*; D019157:Ischemic Preconditioning, Myocardial; D015428:Myocardial Reperfusion Injury / Q000150:complications / Q000378:metabolism / Q000473:pathology; D009206:Myocardium / Q000473:pathology*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D015221:Potassium Channels / Q000378:metabolism
chemical_list: D018031:Connexin 43; D015221:Potassium Channels; C117780:mitochondrial K(ATP) channel; D052250:Nitric Oxide Synthase Type III